2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2699

Mosaic, a Novel Gene, Mediating Autoimmunity in Mice
Abstract Number: 2700

Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis
Abstract Number: 2701

TNFR2+ Regulatory T Cellssubpopulations ARE Highly Suppressive and Are Increased on Anti-TNF Treatment
Abstract Number: 2702

Tissue-Invasive T Cells in Rheumatoid Arthritis
Abstract Number: 2703

Single Cell Analysis of TCRs from CD8+ T Cells in Sjogren’s Syndrome
Abstract Number: 2704

Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Abstract Number: 2705

Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease
Abstract Number: 2706

T Follicular-Helper CELLS (TFH) Enrichment and T Follicular-Regulatory CELLS (TFR) Exclusion from Ectopic Germinal Centers in Salivary Glands of Sjogren’s Syndrome Patients
Abstract Number: 2707

Estrogen Downregulates the Expression of Serine Arginine Splicing Factor 1 (SRSF1) in Human T Lymphocytes
Abstract Number: 2708

Placental Growth Factor Regulates the Generation of T-Helper 17 Cells to Link Angiogenesis with Autoimmunity
Abstract Number: 2709

Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target for Patients with Rheumatoid Arthritis
Abstract Number: 2710

CXCR3+CCR6+CD4+ T Cells (Th1Th17) and RF As Novel Predictive Markers for Clinical Response to Abatacept Treatment in Patients with Rheumatoid Arthritis: The 52-Week Analysis
Abstract Number: 2711

Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Abstract Number: 2712

Autoimmune Arthritis in IL-1 Receptor Antagonist-Deficient Mice Is Associated with a Pathogenic Conversion of Foxp3+ Regulatory T Cells into Th17 Cells
Abstract Number: 2713

CD318 Is a New Ligand for CD6

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].